Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-ViVA phase II trial of low-dose azacitidine + tretinoin + pioglitazone versus standard-dose azacitidine in older patients with refractory AML
2016-000421-39Phase 2Terminated
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Nov 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) comparing Low-dose azacitidine + tretinoin + pioglitazone with Standard-dose azacitidine (2 arms). Primary endpoint: Overall survival. Started Nov 2016; status: terminated.
02
Drugs
azacitidinetretinoinpioglitazone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-000421-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000421-39.